Shares of Abiomed Inc. (NASDAQ:ABMD) have earned a consensus recommendation of “Buy” from the eight ratings firms that are covering the firm. Three research analysts have rated the stock with a hold recommendation, four have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $121.11.

A number of equities analysts recently issued reports on the company. Leerink Swann reiterated an “outperform” rating and issued a $125.00 target price on shares of Abiomed in a report on Wednesday, September 28th. Zacks Investment Research upgraded Abiomed from a “hold” rating to a “strong-buy” rating and set a $146.00 price objective on the stock in a research note on Wednesday, October 5th. Jefferies Group raised their price objective on Abiomed from $130.00 to $145.00 and gave the company a “buy” rating in a research note on Tuesday, August 9th. Finally, TheStreet cut Abiomed from a “buy” rating to a “hold” rating in a research note on Thursday, October 27th.

In related news, CEO Michael R. Minogue sold 5,034 shares of Abiomed stock in a transaction dated Wednesday, September 21st. The stock was sold at an average price of $127.07, for a total value of $639,670.38. Following the completion of the sale, the chief executive officer now owns 215,782 shares of the company’s stock, valued at approximately $27,419,418.74. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Michael R. Minogue sold 28,039 shares of Abiomed stock in a transaction dated Thursday, September 22nd. The stock was sold at an average price of $127.07, for a total value of $3,562,915.73. Following the completion of the sale, the chief executive officer now directly owns 215,488 shares of the company’s stock, valued at approximately $27,382,060.16. The disclosure for this sale can be found here. Insiders own 10.00% of the company’s stock.

A number of large investors have recently made changes to their positions in ABMD. Profund Advisors LLC raised its stake in shares of Abiomed by 13.6% in the third quarter. Profund Advisors LLC now owns 6,143 shares of the company’s stock valued at $790,000 after buying an additional 734 shares during the period. Morgan Stanley raised its stake in shares of Abiomed by 3.9% in the third quarter. Morgan Stanley now owns 296,699 shares of the company’s stock valued at $38,150,000 after buying an additional 11,168 shares during the period. Timpani Capital Management LLC raised its stake in shares of Abiomed by 0.4% in the third quarter. Timpani Capital Management LLC now owns 28,935 shares of the company’s stock valued at $3,720,000 after buying an additional 127 shares during the period. Pacer Advisors Inc. raised its stake in shares of Abiomed by 40.3% in the third quarter. Pacer Advisors Inc. now owns 4,329 shares of the company’s stock valued at $557,000 after buying an additional 1,244 shares during the period. Finally, Stephens Investment Management Group LLC raised its stake in shares of Abiomed by 3.7% in the third quarter. Stephens Investment Management Group LLC now owns 272,241 shares of the company’s stock valued at $35,005,000 after buying an additional 9,763 shares during the period. 93.29% of the stock is owned by institutional investors.

Abiomed (NASDAQ:ABMD) last issued its earnings results on Thursday, October 27th. The company reported $0.20 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.24 by $0.04. Abiomed had a return on equity of 11.63% and a net margin of 11.24%. The firm earned $103 million during the quarter, compared to the consensus estimate of $103.16 million. During the same quarter in the prior year, the business earned $0.17 earnings per share. Abiomed’s revenue for the quarter was up 35.0% on a year-over-year basis.

Abiomed Company Profile

ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.

5 Day Chart for NASDAQ:ABMD

Receive News & Stock Ratings for Abiomed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abiomed Inc. and related stocks with our FREE daily email newsletter.